Nasdaq-listed Theravance Biopharma, has announced a “modified Dutch auction” tender offer to purchase up to US$95m of its ordinary shares, as set out in its US$250m Capital Return Programme, which earlier saw…
Nasdaq-listed Theravance Biopharma, has announced a “modified Dutch auction” tender offer to purchase up to US$95m of its ordinary shares, as set out in its US$250m Capital Return Programme, which earlier saw…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference